Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls.
We performed two semen analyses in each of a small cohort of 11 GH-deficient (GHD) adolescents (mean age 18.1 +/- 0.6 yrs), previously treated (mean 29 months prior) with either GH alone or GH and an aromatase inhibitor (anastrozole) for 12 months and compared their data with those of 10 healthy controls (mean age 18.7 +/- 1.8 yrs). Although some adolescents had lower sperm parameters as compared to adult reference values, mean sperm concentrations, motility, and morphology were comparable among the 3 groups, suggestive that this small group of GHD adolescents previously treated with anastrozole has descriptively similar sperm parameters as other GHD and GH-sufficient adolescent controls.
Mauras
Nelly
N
Nemours Children's Clinic and Research Programs, Jacksonville, Florida 32207, USA. nmauras@nemours.org
Bell
Jennifer
J
Snow
Banae G
BG
Winslow
Kevin L
KL
D000293:Adolescent; D000328:Adult; D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D015331:Cohort Studies; D019382:Human Growth Hormone / Q000172:deficiency* / Q000494:pharmacology / Q000592:standards; D006801:Humans; D008297:Male; D009570:Nitriles / Q000494:pharmacology*; D012015:Reference Standards; D012016:Reference Values; D013076:Sperm Count / Q000592:standards / Q000706:statistics & numerical data; D013094:Spermatozoa / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D014230:Triazoles / Q000494:pharmacology*
D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D019382:Human Growth Hormone; D000077384:Anastrozole